GSK Australia welcomes the listing of Shingrix (Recombinant Varicella Zoster Virus glycoprotein E antigen (AS01B adjuvanted vaccine)) on the National Immunisation Program (NIP) for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in Australia on November 1.
Shingrix is the first non-live vaccine to be listed on the NIP for the preven
Subscribe to Wangaratta Chronicle to read the full story.